Rejection Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Rejection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Graft vs Host DiseaseGraft-versus-leukemiaGraft Rejection
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00106925
Recruiting

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Cardiac FailureGraft Rejection
Inova Health Care Services150 enrolled7 locationsNCT06532890
Recruiting

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

Cardiac FailureGraft Rejection
Inova Health Care Services250 enrolled5 locationsNCT06939751
Recruiting
Phase 1

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

Chronic Kidney DiseasesEnd-stage Kidney DiseaseImmunological Tolerance+1 more
University of California, Los Angeles10 enrolled1 locationNCT05525507
Recruiting
Not Applicable

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

MesotheliomaAtelectasisPneumothorax+11 more
Brigham and Women's Hospital230 enrolled1 locationNCT06538376
Recruiting
Early Phase 1

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Chronic Myeloid LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma+9 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins8 enrolled1 locationNCT06398457
Recruiting
Phase 2Phase 3

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

Heart Transplant InfectionCMV ViremiaHeart Transplant Failure and Rejection
Columbia University150 enrolled2 locationsNCT07079735
Recruiting
Not Applicable

TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation

CancerInfectionKidney Transplantation+1 more
Hospices Civils de Lyon300 enrolled4 locationsNCT06829719
Recruiting
Phase 1Phase 2

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

Liver CancerLiver MetastasesLiver Cirrhosis+4 more
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC90 enrolled1 locationNCT07053488
Recruiting
Phase 1Phase 2

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

Kidney FailureEnd Stage Renal DiseaseKidney Tumor+4 more
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC90 enrolled1 locationNCT07053462
Recruiting
Phase 1Phase 2

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Prevention of Rejection in Kidney Transplant
Eledon Pharmaceuticals48 enrolled9 locationsNCT05027906
Recruiting

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Chronic Kidney DiseaseLiver TransplantHepatitis C+1 more
Northwestern University1,000 enrolled1 locationNCT01644903
Recruiting

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

Heart FailureLiver FibrosisCardiac Transplant Rejection+1 more
Arunark Kolipaka1,000 enrolled1 locationNCT01757730
Recruiting
Phase 4

Allograft Dysfunction in Heart Transplant

Heart Transplant Failure and Rejection
Paul Kim376 enrolled1 locationNCT03102125
Recruiting

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

Acute Rejection (AR) of Transplanted KidneyChronic Allograft Nephropathy (CAN)Interstitial Fibrosis (IF)+1 more
Northwestern University1,000 enrolled1 locationNCT01531257
Recruiting
Not Applicable

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

Graft vs Host DiseaseGraft RejectionCutaneous T Cell Lymphoma
Centre Hospitalier Universitaire de Besancon20 enrolled1 locationNCT05333367
Recruiting
Phase 4

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

Graft RejectionGraft FailureRenal Failure Chronic+2 more
Hospital Universitari Vall d'Hebron Research Institute202 enrolled1 locationNCT06676696
Recruiting

A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients

Heart Transplant Failure and Rejection
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT05994274